Skip to main content

Table 1 Baseline patient and lesion characteristics

From: The impact of vildagliptin on the daily glucose profile and coronary plaque stability in impaired glucose tolerance patients with coronary artery disease: VOGUE—A multicenter randomized controlled trial

Variables Vildagliptin group (n = 10) Control group (n = 10) p Value
Men, % 100 80 0.474
Age, years 65.9 ± 10.6 68.3 ± 8.1 0.820
BMI, kg/m2 24.0 ± 4.0 24.0 ± 4.5 0.909
Smoker, % 70 40 0.133
Familial history, % 10 10 1.000
Stable angina, % 100.0 100.0  
Revascularization vessel, %    0.409
 Right coronary artery, % 31.8 34.6  
 Left main coronary trunk, % 18.2 7.7  
 Left anterior descending coronary artery, % 31.8 34.6  
 Left circumflex coronary artery, % 18.2 23.1  
Medication, %
 Beta blocker, % 70.0 50.0 0.649
 ACE-I/ARB, % 50.0 50.0 1.000
 Statin, % 90.0 100.0 1.000
 Other oral DM drugs, % (except DPP-4 inhibitors) 0.0 0.0  
 Insulin, % 0.0 0.0  
 Prasugrel, % 40.0 60.0 0.656
 Clopidogrel, % 60.0 40.0 0.656
 Aspirin, % 100.0 100.0 0
Laboratory data
 LDL cholesterol, mg/dl 84.0 ± 14.3 82.9 ± 27 0.791
 HDL cholesterol, mg/dl 47.4 ± 14.8 41.5 ± 9.8 0.289
 Triglyceride, mg/dl 118.4 ± 52.1 131.6 ± 77.9 0.939
 Creatinine, mg/dl 0.8 ± 0.1 0.9 ± 0.3 1.000
 1,5 AG, μg/ml 19.9 ± 4.1 22.0 ± 4.1 0.377
 HbA1c (NGSP), % 5.9 ± 0.3 5.9 ± 0.4 0.845
 HOMA R 1.5 ± 5.7 1.5 ± 0.6 0.909
 CRP, mg/dl 0.2 ± 0.4 0.2 ± 0.2 0.879
75 g OGTT
 Fast glucose, mg/dl 97.2 ± 9.0 94.2 ± 11.9 0.471
 2-h glucose, mg/dl 185.7 ± 36.6 169.5 ± 20.5 0.405
 Fast IRI, μU/ml 6.6 ± 3.5 6.3 ± 2.7 1.000
 2-h IRI, μU/ml 114.1 ± 80.3 101.3 ± 75.6 0.791
  1. Mean ± standard deviation (n) for continuous variables; frequency count (%) for categorical variables 1,5 AG = 1,5 anhydroglucitol; 75 g OGTT = 75 g oral glucose tolerance test; ACE-I = angiotensin converting enzyme-inhibitor; ARB = angiotensin II receptor blocker; BMI = body mass index; CRP = C-reactive protein; DM = diabetes mellitus; DPP-4 = dipeptidyl peptidase-4; HbA1c = glycated hemoglobin; HDL = high-density lipoprotein; HOMA R = homeostasis model assessment ratio; IRI = immunoreactive insulin; LDL = low-density lipoprotein; NGSP = national glycohemoglobin standardization program